Parse Biosciences

Executive Summary

Parse Biosciences is a Seattle-based biotechnology company founded in 2018 that has developed a disruptive single-cell sequencing platform called Evercode™. Unlike traditional methods that require expensive microfluidic instruments, Parse's technology enables scalable, instrument-free single-cell profiling, making it accessible to a broader range of researchers. The company offers an end-to-end workflow from sample preparation to data analysis via its Trailmaker software. With a focus on democratizing single-cell genomics, Parse has positioned itself as a key player in the rapidly growing single-cell sequencing market, which is projected to exceed $5 billion by 2027. The company's innovative approach and comprehensive solution have attracted significant interest from the research community, though it faces competition from established players like 10x Genomics. Parse's continued success hinges on its ability to scale operations, expand its product portfolio, and forge strategic partnerships to drive adoption across diverse applications such as oncology, immunology, and developmental biology.

Upcoming Catalysts (preview)

• Q4 2026Launch of next-generation Evercode chemistry with improved sensitivity and throughput75% success
• Q2 2026Key partnership with a major pharmaceutical company for drug discovery applications60% success
• Q1 2027Release of Trailmaker software update enabling multi-omic data integration80% success